| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 14 unusual trades.
Delving into the details, we found 14% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $721,270, and 10 were calls, valued at $1,045,138.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $960.0 to $1280.0 for Regeneron Pharmaceuticals over the last 3 months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Regeneron Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Regeneron Pharmaceuticals's significant trades, within a strike price range of $960.0 to $1280.0, over the past month.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | CALL | TRADE | NEUTRAL | 01/17/25 | $160.3 | $152.0 | $156.6 | $980.00 | $454.1K | 200 | 0 |
| REGN | PUT | TRADE | BEARISH | 06/20/25 | $99.0 | $91.5 | $96.0 | $1100.00 | $384.0K | 3 | 0 |
| REGN | PUT | TRADE | NEUTRAL | 12/18/26 | $112.0 | $102.0 | $107.0 | $1040.00 | $214.0K | 0 | 0 |
| REGN | CALL | TRADE | BEARISH | 06/20/25 | $58.0 | $55.0 | $55.0 | $1280.00 | $165.0K | 19 | 0 |
| REGN | PUT | TRADE | BEARISH | 01/17/25 | $33.5 | $27.3 | $31.3 | $980.00 | $90.7K | 117 | 0 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Following our analysis of the options activities associated with Regeneron Pharmaceuticals, we pivot to a closer look at the company's own performance.
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1195.6.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
Posted In: REGN
